Advertisement

Modelos de simulación de eventos discretos: ¿por qué, cómo y cuándo?

  • Javier Soto Álvarez
Artículo de Investigación Original
  • 34 Downloads

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Bibliografía

  1. 1.
    Briggs AH, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 1998; 13: 397–409.PubMedCrossRefGoogle Scholar
  2. 2.
    Eddy D. Bringing health economic modelling to the 21st century. Value Health 2006; 9: 168–78.PubMedCrossRefGoogle Scholar
  3. 3.
    Law A, Kelton W. Simulation modelling and analysis. 3rd edition. McGraw Hill: Boston 2000.Google Scholar
  4. 4.
    Banks J, Carson JS, Nelson BL. Discrete event system simulation. Englewood Cliffs: Prentice-Hall, 1996.Google Scholar
  5. 5.
    Stahl JE. Modelling methods for pharmacoeconomics and health technology assessment. An overview and guide. Pharmacoeconomics 2008; 26: 131–48.PubMedCrossRefGoogle Scholar
  6. 6.
    Rodriguez Barrios JM, Serrano D, Monleón T, Caro J. Los modelos de simulación de eventos discretos en la evolución económica de tecnologías y productos sanitarios. Gac Sanit 2008; 22: 151–61.PubMedCrossRefGoogle Scholar
  7. 7.
    Hollingworth W, Spackman E. Emerging methods in economic modeling of Imaging costs and outcomes: A short Report on discrete event simulation. Acad Radiol 2007; 14: 406–10.PubMedCrossRefGoogle Scholar
  8. 8.
    Ramwadhdoebe S, Buskens E, Sakkers RUB, Stahl JE. A tutorial on discrete-event simulation for health policy design and decision making: optimizing paediatric ultrasound screening for hip dysplasia as an illustration. Health Policy 2009 (doi: 10.1016/j.healthpol.2009.07.007).Google Scholar
  9. 9.
    Caro JJ. Pharmacoeconomic analyses using discrete event simulation. Pharmacoeconomics 2005; 23: 323–32.PubMedCrossRefGoogle Scholar
  10. 10.
    Karnon J. Alternative decision modelling techniques for the evaluation of healthcare technologies: Markov processes versus discrete event simulation. Health Econ 2003; 12: 837–48.PubMedCrossRefGoogle Scholar
  11. 11.
    Simpson KN, Strassburger A, Jons WJ, Dietz B, Rajagopalan R. Comparison of Markov model and discrete-event simulation techniques for HIV. Pharmacoeconomics 2009; 27: 159–65.PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2009

Authors and Affiliations

  • Javier Soto Álvarez
    • 1
  1. 1.Unidad Médica. Pfizer EspañaDpto. de Investigación de Resultados en Salud y FarmacoeconomíaAlcobendas (Madrid)España

Personalised recommendations